Riluzole (Aquestive Therapeutics)

利鲁唑 (Aquestive Therapeutics)

Report date: 2026/01/29 16:55:28

Base Information

Drug NameRiluzole (Aquestive Therapeutics)
Drug Alias Name利鲁唑口溶膜Riluzole OSFRiluzole oral soluble filmExservanEmylif +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockersGlutamate release inhibitors
TargetsSodium channel alpha subunit
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsAmyotrophic Lateral Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/22
Country/TerritoryUnited StatesEUMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesAquestive Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesZambonZambon Spa
Inactive CompaniesAquestive Therapeutics Inc
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN07XX02
Related LinksN/A